Perrigo Co. said early Tuesday that it has filed for Food and Drug Administration approval for a generic version of Valeant Pharmaceuticals International Inc.’s Onexton acne gel. Valeant filed a lawsuit claiming patent infringement last week, Perrigo said. Onexton sales for 12 months through December 2016 totaled about $139 million, Perrigo said. Perrigo shares have dropped 7.0% over the last three months and Valeant shares have dropped 23.7%, compared with a 7.6% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News